Skip to main content

Advertisement

SpringerLink
Log in

Expression of caveolin-1 is correlated with lung adenocarcinoma proliferation, migration, and invasion

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

A Correction to this article was published on 29 September 2022

This article has been updated

Abstract

Both tumor suppressor and tumor promoter roles, which are dependent on the tumor type, have been described for caveolin-1 (CAV-1). Because CAV-1 can modulate cell signaling, we tested the hypothesis that it regulates lung adenocarcinoma cell proliferation and metastasis via modulation of epidermal growth factor receptor (EGFR) activity. The lung adenocarcinoma cell line, GLC-82, was transfected with pcDNA3.1CAV-1 plasmid, before cell proliferation, migration, and invasion were analyzed. In the in vivo xenograft model, the relationship between the CAV-1 expression and EGFR phosphorylation and signaling was assessed by western blot analysis. The relationship between the CAV-1 as well as Ki67 expression and the clinicopathological characteristics of 68 lung adenocarcinoma patients was also examined using immunohistochemistry. Overexpression of CAV-1 significantly increased GLC-82 proliferation (p < 0.001), migration (p < 0.001), and invasion (p = 0.002) as well as EGFR and ERK phosphorylation (p < 0.05). The GLC-82/CAV-1 cell tumors were also significantly larger than those of control cells (all p ≤ 0.05). In lung adenocarcinoma patients, CAV-1 expression was positively correlated with lymph node metastasis and cancer stage. Finally, CAV-1 expression was associated with the expression of Ki-67, a marker of cell proliferation. CAV-1 enhanced GLC-82 cell proliferation, migration, and invasion possibly through EGFR and ERK signaling. Furthermore, the relationship of CAV-1 with Ki67 expression, a marker of proliferative capacity, in lung adenocarcinoma samples is suggestive of its role in disease progression. Further studies are required to confirm the role of CAV-1 in the metastasis of lung adenocarcinoma as well as its potential prognostic and therapeutic value.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

Change history

References

  1. Ahannan SV, Brahmer JR. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest. 2011;29:325–37.

    Article  Google Scholar 

  2. Stinchcombe TE. Recent advances in the treatment of non-small cell and small cell lung cancer. F1000Prime Rep. 2014;6:117.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Filosto S, Becker CR, Goldkorn T. Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors. Mol Cancer Ther. 2012;11:795–804.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Luetterforst R, Stang E, Zorzi N, Carozzi A, Way M, Parton RG. Molecular characterization of caveolin association with the Golgi complex: identification of a cis-Golgi targeting domain in the caveolin molecule. J Cell Bio. 1999;145:1443–59.

    Article  CAS  Google Scholar 

  5. Glenney JR, Soppet D. Sequence and expression of caveolin, a protein component of caveolae plasma-membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts. Proc Natl Acad Sci USA. 1992;89:10517–21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol. 2005;288(3):494–506.

    Article  Google Scholar 

  7. Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem. 1997;272:30429–38.

    Article  CAS  PubMed  Google Scholar 

  8. Engelman JA, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, et al. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett. 1995;428:205–11.

    Article  Google Scholar 

  9. Li S, Okamoto T, Chun M, Sargiacomo M, Casanova JE, Hansen SH, et al. Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem. 1995;270:15693–701.

    Article  CAS  PubMed  Google Scholar 

  10. Razani B, Rubin CS, Lisanti MP. Regulation of cAMP mediated signal transduction via interaction of caveolins with the catalytic subunit of protein kinase A. J Biol Chem. 1999;274:26353–60.

    Article  CAS  PubMed  Google Scholar 

  11. Conde MC, Ramirez-Lorca R, Lopez-Jamar JM, Molero E, Ramírez-Armengol JA, Moreno Nogueira JA, et al. Genetic analysis of Caveolin-1 and eNOS genes in colorectal cancer. Oncol Rep. 2006;16:353–9.

    CAS  PubMed  Google Scholar 

  12. Bouras T, Lisanti MP, Pestell RG. Caveolin-1 in breast cancer. Cancer Biol. 2004;3:931–41.

    Article  CAS  Google Scholar 

  13. Kato T, Miyamoto M, Kato K, Cho Y, Itoh T, Morikawa T, et al. Difference of caveolin-1 expression pattern in human lung neoplastic tissue. Atypical adenomatous hyperplasia, adenocarcinoma and squamous cell carcinoma. Cancer Lett. 2004;214(1):121–8.

    Article  CAS  PubMed  Google Scholar 

  14. Bender FC, Reymond MA, Bron C, Quest AF. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res. 2000;60:5870–8.

    CAS  PubMed  Google Scholar 

  15. Wiechen K, Diatchenko L, Agoulnik A, Scharff KM, Schober H, Arlt K, et al. Caveolin–1 is downregulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol. 2001;159:1635–40.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Razani BA, Itschuler Y, Zhu L, Pestell RG, Mostov KE, Lisanti MP. Caveolin-1 expression is downregulated in cells transformed by the human papilloma virus in a P53-dependent manner replacement of Caveolin-1 expression suppresses HPV-mediated cell transformation. Biochemisty. 2000;39(45):13916–24.

    Article  CAS  Google Scholar 

  17. Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 1999;59:5719–23.

    CAS  PubMed  Google Scholar 

  18. Horiguchi A, Asano T, Asakuma J, Asano T, Sumitomo M, Hayakawa M. Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma. J Urol. 2004;172:718–22.

    Article  CAS  PubMed  Google Scholar 

  19. Fong A, Garcia E, Gwynn L, Lisanti MP, Fazzari MJ, Li M. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. J Am J Clin Pathol. 2003;120:93–100.

    Article  CAS  Google Scholar 

  20. Chen D, Shen C, Du H, Zhou Y, Che G. Duplex value of caveolin-1 in non-small cell lung cancer: a meta analysis. Fam Cancer. 2014;13:449–57.

    Article  CAS  PubMed  Google Scholar 

  21. Morrison DK, Davis RJ. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu Rev Cell Dev Biol. 2003;19:91–118.

    Article  CAS  PubMed  Google Scholar 

  22. Morgillo F, Martinelli E, Troiani T, Orditura M, De Vita F, Ciardiello F. Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. PLoS ONE. 2011;6:e28841.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Yi WY, Hong W, Kang HJ, Kim HJ, Zhao W, Wang A, et al. Inhibition of the PI3 K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells. J Cell Mol Med. 2013;17:648–56.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Filaria JL, Zhu TN, O’Connell MP, Hoek KS, Indig FE, Frank BP, et al. Filamin A modulates kinase activation and intracellular trafficking of epidermal growth factor receptors in human melanoma cells. Endocrinology. 2009;150:2551–60.

    Article  Google Scholar 

  25. Pancotti F, Roncuzzi L, Maggiolini M, Gasperi-Campani A. Caveolin-1 silencing arrests the proliferation of metastatic lung cancer cells through the inhibition of STAT3 signaling. Cell Signal. 2007;24:1390–7.

    Article  Google Scholar 

  26. Ha TK, Her NG, Lee MG, Ryu BK, Lee JH, Han J, et al. Caveolin-1 increases aerobic glycolysis in colorectal cancers by stimulating HMGA1-mediated GLUT3 transcription. Cancer Res. 2012;72:4097–109.

    Article  CAS  PubMed  Google Scholar 

  27. Linge A, Weinhold K, Bläsche R, Kasper M, Barth K. Downregulation of caveolin-1 affects bleomycin-induced growth arrest and cellular senescence in A549 cells. Int J Biochem Cell Biol. 2007;39:1964–74.

    Article  CAS  PubMed  Google Scholar 

  28. Han F, Zhang J, Shao J, Yi X. Caveolin-1 promotes an invasive phenotype and predicts poor prognosis in large cell lung carcinoma. Pathol Res Pract. 2014;210:514–20.

    Article  CAS  PubMed  Google Scholar 

  29. Cassoni P, Daniele L, Maldi E, Righi L, Tavaglione V, Novello S, et al. Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases. Histopathology. 2009;55:20–7.

    Article  PubMed  Google Scholar 

  30. Wang Y, Liu B, Xu Y, Zhang J, Xia Q, Yu B, et al. Correlation of caveolin-1 expression with clinicopathologic features and prognosis in patients with lung adenocarcinoma. Chinese Journal of Pathology. 2014;43:251–5.

    PubMed  Google Scholar 

  31. Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, Hsu SM. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol. 2002;61:1647–56.

    Article  Google Scholar 

  32. Kirita K, Ishii G, Matsuwaki R, Matsumura Y, Umemura S, Matsumoto S, et al. Identification of biological properties of intralymphatic tumor related to the development of lymph node metastasis in lung adenocarcinoma. PLoS ONE. 2013;8:e83537.

    Article  PubMed Central  PubMed  Google Scholar 

  33. Rendon BE, Roger T, Teneng I, Zhao M, Al-Abed Y, Calandra T, et al. Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J Biol Chem. 2007;282:29910–8.

    Article  CAS  PubMed  Google Scholar 

  34. Chen HL, Fan LF, Gao J, Ouyang JP, Zhang YX. Differential expression and function of the caveolin-1 gene in non-small cell lung carcinoma. Oncol Rep. 2011;25:359–66.

    PubMed  Google Scholar 

  35. Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res. 2005;11:5878–85.

    Article  CAS  PubMed  Google Scholar 

  36. Liu HX, Xing LX, Wang HB, Yang JQ, Sun YM. Relationship between expression of caveolin-1 and pERK1/2 and prognosis in non-small cell lung cancer. Chinese Journal of Pathology. 2008;37(9):615–9.

    CAS  PubMed  Google Scholar 

  37. Zhan P, Shen XK, Qian Q, Wang Q, Zhu JP, Zhang Y, et al. Expression of caveolin-1 is correlated with disease stage and survival in lung adenocarcinomas. Oncol Rep. 2012;27(4):1072–8.

    CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 81071846, to T.N.Z); Natural Science Foundation of Hebei Province of China (No. H2013505059, to T.N.Z); Department of Science and Technology of Hebei Province of China (No. 12396107D, to R.J.Z, No. 09966114D, and No. 092461102D, to T.N.Z); Wu Jieping Foundation (No. 320.6750.12604, and No. 320.6750.14063, to T.N.Z).

Author information

Authors and Affiliations

  1. Department of Oncology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China

    Tian-Yan Luan, Tie-Nian Zhu, Yu-Jie Cui, Gang Zhang & Xue-Jing Song

  2. Department of Medical Oncology, Bethune International Peace Hospital, Shijiazhuang, 050082, Hebei, China

    Tie-Nian Zhu, Dong-Mei Gao, Yi-Mei Zhang, Qing-Lan Zhao & Tong-Yi Su

  3. Department of Pathology, Bethune International Peace Hospital, Shijiazhuang, 050082, Hebei, China

    Shuang Liu

  4. Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Department of Immunology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China

    Rui-Jing Zhao

Authors
  1. Tian-Yan Luan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tie-Nian Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yu-Jie Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xue-Jing Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dong-Mei Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yi-Mei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Qing-Lan Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shuang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tong-Yi Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Rui-Jing Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Tie-Nian Zhu or Rui-Jing Zhao.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Luan, TY., Zhu, TN., Cui, YJ. et al. Expression of caveolin-1 is correlated with lung adenocarcinoma proliferation, migration, and invasion. Med Oncol 32, 207 (2015). https://doi.org/10.1007/s12032-015-0644-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-015-0644-5

Keywords

Search

Navigation